Precision Scientific Secures RMB 150 Million Series B Financing to Advance Multi-Omics Data Mining for Innovative Drug Discovery

Recently, Precision Scientific (Beijing) Co., Ltd. (hereinafter referred to as "Precision Scientific") completed a Series B financing round of RMB 150 million. This round was co-led by Suzhou Kington Capital Co., Ltd. and GTJA INVESTMENT GROUP, with Qichen Capital and Grand Mount Capital participating. Existing investors Beijing Hulian Innovation Works Investment Management Limited and Shenzhen Maison Capital Co., Ltd. made additional investments.

This round of financing will empower the company with enhanced capabilities to assist pharmaceutical partners in developing innovative and differentiated pipelines, including systematically strengthening its competencies in translational medicine/medical affairs, and accelerating the company's AIBERT^®The upgrade of the (Oncology Multi-omics Data Mining System for New Drug Development) platform leverages omics data mining to support original innovation in pharmaceutical R&D, reinforcing the company’s position as a “new R&D partner for pharmaceutical companies.”

Dr. Xuwo Ji, Founder & CEO of Precision Scientificsaid: "We extend our sincere gratitude to both new and existing investors for their recognition and support of Precision Scientific. Pioneering original innovation in new drug development represents a formidable challenge not only for Chinese pharmaceutical enterprises but also for the global drug R&D industry. Addressing the emerging challenges in this field requires us to systematically enhance our understanding of complex biological systems and better decode the holistic regulatory networks of diseases (e.g., tumors). This will, in turn, elevate our capacity to evaluate and discover targets, indications, and biomarkers at the molecular mechanism level. Driven by the rapid expansion of data generated by multi-omics technologies (such as single-cell sequencing) and advancements in AI algorithms including deep learning and causal inference, we are, for the first time in history, positioned to derive this 'answer' (system-level capability) directly from data. Consequently, we are empowered to apply this 'new knowledge' of biological mechanisms to new drug development, thereby driving innovative and differentiated therapeutic development."Professor Liang Han, Co-founder of the CompanyIt was also emphasized: "Over the past decade, clinical sample-based multi-omics represented by The Cancer Genome Atlas (TCGA), functional omics represented by DepMap, and single-cell omics represented by the Human Cell Atlas (HCA) have provided a rich data foundation, systematic frameworks, and increasingly mature analytical technologies for understanding disease mechanisms and developing effective therapeutic strategies. This has enabled the realization of Precision Scientific’s vision: to integrate the most valuable omics data with cutting-edge artificial intelligence algorithms to comprehensively empower partners, thereby providing a powerful driving force for novel drug development and precision medicine practices in China."

Mr. Lin Xianghong, Founding Partner of Kington Capitalstated: “Competition in China’s innovative drug R&D industry is becoming increasingly intense, making differentiation a critical objective in drug development. Emerging data-driven models have proven effective and are playing an increasingly vital role across all stages of the drug development pipeline. Under the leadership of its founders, Dr. Ji Xuwo and Prof. Liang Han, Precision Scientific has established an internationally leading bioinformatics team and a high-standard experimental platform. Leveraging years of accumulated bioinformatics data and its proprietary AI system, the company provides pharmaceutical enterprises with end-to-end translational medicine services, spanning from R&D project initiation and preclinical research to clinical trials and drug commercialization. Since its inception, its client base has continuously expanded alongside a steadily growing reputation. We are highly honored to lead this round of financing and look forward to the company’s sustained business growth, as it makes significant contributions to the advancement of China’s innovative drug R&D sector.”

Ms. Fan Wenjing, Executive Partner at GTJA Investmentstated: "The intelligent transformation of new drug discovery is underway. Leveraging algorithms to mine omics data and achieve a deeper understanding of the molecular mechanisms of diseases constitutes the 'deep water zone' of AI drug discovery, which requires addressing challenges in multi-omics data mining, such as the heterogeneity, high dimensionality, dynamics, and sparsity of high-throughput omics data. As a pioneer in this field in China, Precision Scientific has independently developed AIBERT, a multi-omics data mining platform tailored for oncology new drug discovery,^®, effectively addressing this challenge, and demonstrating significant advantages in enhancing R&D efficiency across key areas such as novel target evaluation, as well as the selection and expansion of new indications. In recent years, its collaborations with multiple international pharmaceutical companies, providing a one-stop solution from R&D decision-making to CDx, have fully validated AIBERT^®the market value of the platform. We chose to invest in Precision Scientific precisely because of our confidence in the high growth potential of AI-driven drug discovery and the team's relentless drive for continuous breakthroughs. We believe that Precision Scientific will unlock limitless possibilities for future drug R&D, further strengthening China's AI innovation capabilities.”

Ms. Wang Meinong, Executive Director of Grand Mount Capitalstated: "Insufficient understanding of disease biological mechanisms has become a key driver of the rapid decline in new drug R&D ROI in recent years, compelling numerous Chinese innovative drug developers to engage in fierce, homogeneous competition over a limited pool of targets. Unlike most AI pharmaceutical companies that focus primarily on drug discovery (drug structure design), Precision Scientific leverages multi-omics data mining to build a profound understanding of biological mechanisms. This approach uncovers numerous 'differentiated' innovations throughout the drug development process, enhances R&D success rates, and thereby demonstrates its unique value. We firmly believe that Precision Scientific will emerge as a world-class platform company empowering pharmaceutical R&D. Going forward, it will help more pharmaceutical and biotechnology companies develop more highly effective therapeutics, ultimately benefiting patients worldwide."

This financing round will enable Precision Scientific to further strengthen its technology platform, advance R&D collaborations with pharmaceutical partners, and provide comprehensive support throughout the entire new drug development lifecycle, powered by multi-omics and data mining. We look forward to more outstanding talents joining the visionary, passionate, and action-oriented Precision Scientific team to dedicate themselves to the exciting mission of "harnessing omics data mining to drive new drug development."

Precision Scientific is a novel platform company driven by "multi-omics + data mining," specializing in differentiated R&D strategies for innovative drugs. Centered on advanced multi-omics technologies, bioinformatics, and AI algorithms, the company is built upon its independently developed, AI-driven massive multi-omics data mining system, AIBERT^®, providing pharmaceutical and biotechnology companies with globally leading innovative services such as drug mechanism of action research, biomarker discovery, biomarker-based differentiated R&D strategies, clinical biostatistics, central laboratory services, and companion diagnostic development. The company has currently established in-depth collaborations with numerous leading domestic and international pharmaceutical and biotech firms, facilitating the research, development, and regulatory approval of multiple new drugs. Meanwhile, in the clinical setting, the company has cultivated a collaborative ecosystem with pharmaceutical companies and physicians to deliver advanced testing services to patients, thereby advancing the clinical practice of precision medication.

Founded in 2016, Kington Capital is a private equity fund management platform wholly established by Suzhou Private Capital Investment Holding Co., Ltd. Its core management team has been deeply engaged in private equity investment, bringing nearly two decades of practical experience in technology enterprise financing and investment, as well as leveraging capital to drive the synergistic development of industries. The team has accumulated extensive investment expertise and a proven track record of success in strategic emerging sectors such as biomedicine and next-generation information technology. Guided by an innovative investment management philosophy, Kington Capital strategically focuses on and invests in industries that align with the long-term sustainable development requirements of China’s economy, the direction of economic structural transformation and adjustment, and sectors supported and encouraged by national policies. The firm primarily invests in biomedicine, next-generation information technology, and branded consumer goods.

Founded in Shenzhen in 2001, GTJA Investment Group specializes in investments within the medical and healthcare sector. Guided by strategic equity investments, its portfolio spans all investment stages, including private equity (PE), venture capital (VC), angel investments, and mergers & acquisitions (M&A). Boasting one of the largest professional healthcare investment teams in China, the Group has built a comprehensive investment ecosystem platform for the medical and healthcare industry. With assets under management (AUM) exceeding RMB 20 billion, it manages 25 healthcare-focused funds (including USD-denominated funds). To date, GTJA has invested in over 150 companies (more than 80 of which are in the healthcare sector) and successfully guided 31 portfolio companies to IPO. The Group currently operates regional centers in Shenzhen, Shanghai, Beijing, Nanjing, and Hong Kong. Committed to becoming a globally influential medical and healthcare investment institution, it aims to empower entrepreneurs to build exceptional enterprises.

Qichen Capital is an equity investment firm specializing in the high-tech sector, with a focus on industries possessing long-term growth potential, including biopharmaceuticals and advanced technologies. Leveraging an in-depth understanding of these fields, the firm adheres to the philosophy of empowering outstanding companies and teams through capital. By identifying and unlocking the potential of its investment targets, Qichen Capital is committed to delivering long-term, stable returns for its investors.

Established in 2019, Grand Mount Capital is an emerging healthcare investment institution jointly founded by a professional investment team and state-owned capital. Focused on long-term investments in the biopharmaceutical and medical device sectors, the firm systematically invests in high-quality targets within niche sub-segments that feature breakthrough and innovative technologies. Through in-depth partnerships with multiple industry institutions, it adheres to an investment strategy of “industry empowerment + capital support,” aiming to deliver long-term, stable investment returns to its investors.

Founded by Dr. Kai-Fu Lee in September 2009, Sinovation Ventures is a domestic venture capital institution deeply engaged in artificial intelligence & frontier technologies, automation, B2B enterprise services, healthcare, consumer, and education sectors. Through continuous exploration and innovation, it is committed to building a comprehensive ecosystem investment service platform that integrates entrepreneurial platforms, financial support, post-investment services, and more.

Maison Capital is a domestic private equity fund management institution specializing in equity investments, with its investment focus concentrated across four core sectors: consumer, services, healthcare, and technology. For years, the Maison team has dedicated itself to in-depth investment research within a select number of industries. Through a rigorous risk control framework and institutionalized investment operations, the firm has consistently maintained strong long-term investment performance.